Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Trevena stock opened at $1.25 on Thursday. Trevena has a twelve month low of $1.13 and a twelve month high of $11.50. The firm has a market cap of $1.08 million, a PE ratio of -0.03 and a beta of 1.05. The firm’s 50 day moving average price is $1.60 and its two-hundred day moving average price is $2.11.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.